Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review

Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte detachment and apoptosis through interferon-gamma (IFN-γ secretion and chemokines secreted by keratinocytes through...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fei Qi, Fang Liu, Ling Gao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	vitiligo JAK/STAT-1 signaling pathway JAK inhibitors chemokines IFN - interferon Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/a921fbdc232d4cdf94130c0bf445fb7b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a921fbdc232d4cdf94130c0bf445fb7b
record_format	dspace
spelling	oai:doaj.org-article:a921fbdc232d4cdf94130c0bf445fb7b2021-11-18T06:31:12ZJanus Kinase Inhibitors in the Treatment of Vitiligo: A Review1664-322410.3389/fimmu.2021.790125https://doaj.org/article/a921fbdc232d4cdf94130c0bf445fb7b2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.790125/fullhttps://doaj.org/toc/1664-3224Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte detachment and apoptosis through interferon-gamma (IFN-γ secretion and chemokines secreted by keratinocytes through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT)-1 signaling pathway results in further recruitment of CXCR3+ CD8+ T cells and the formation of a positive-feedback loop. JAK inhibitors target the JAK/STAT pathway and are now approved to treat many immune-related diseases. In the treatment of vitiligo, JAK inhibitors, including ruxolitinib, baricitinib, and tofacitinib, are effective, supporting the implication of the IFN-γ-chemokine signaling axis in the pathogenesis of vitiligo. However, more studies are required to determine the ideal dosage of JAK inhibitors for the treatment of vitiligo, and to identify other inflammatory pathways that may be implicated in the pathogenesis of this condition.Fei QiFang LiuLing GaoFrontiers Media S.A.articlevitiligoJAK/STAT-1 signaling pathwayJAK inhibitorschemokinesIFN - interferonImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	vitiligo JAK/STAT-1 signaling pathway JAK inhibitors chemokines IFN - interferon Immunologic diseases. Allergy RC581-607
spellingShingle	vitiligo JAK/STAT-1 signaling pathway JAK inhibitors chemokines IFN - interferon Immunologic diseases. Allergy RC581-607 Fei Qi Fang Liu Ling Gao Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
description	Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte detachment and apoptosis through interferon-gamma (IFN-γ secretion and chemokines secreted by keratinocytes through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT)-1 signaling pathway results in further recruitment of CXCR3+ CD8+ T cells and the formation of a positive-feedback loop. JAK inhibitors target the JAK/STAT pathway and are now approved to treat many immune-related diseases. In the treatment of vitiligo, JAK inhibitors, including ruxolitinib, baricitinib, and tofacitinib, are effective, supporting the implication of the IFN-γ-chemokine signaling axis in the pathogenesis of vitiligo. However, more studies are required to determine the ideal dosage of JAK inhibitors for the treatment of vitiligo, and to identify other inflammatory pathways that may be implicated in the pathogenesis of this condition.
format	article
author	Fei Qi Fang Liu Ling Gao
author_facet	Fei Qi Fang Liu Ling Gao
author_sort	Fei Qi
title	Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
title_short	Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
title_full	Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
title_fullStr	Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
title_full_unstemmed	Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
title_sort	janus kinase inhibitors in the treatment of vitiligo: a review
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/a921fbdc232d4cdf94130c0bf445fb7b
work_keys_str_mv	AT feiqi januskinaseinhibitorsinthetreatmentofvitiligoareview AT fangliu januskinaseinhibitorsinthetreatmentofvitiligoareview AT linggao januskinaseinhibitorsinthetreatmentofvitiligoareview
_version_	1718424499203866624

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review

Ejemplares similares